Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)
NCT ID: NCT03222973
Last Updated: 2022-04-28
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
263 participants
INTERVENTIONAL
2017-11-15
2021-02-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The secondary objective of Part 1 is to evaluate the effects of BIIB033 versus placebo on additional measures of disability improvement. The secondary objective of Part 2 is to investigate long-term efficacy (disability improvement) and additional safety measures of BIIB033 as an add-on therapy in participants with MS.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety Study of BIIB033 in Subjects With Multiple Sclerosis
NCT01244139
Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)
NCT04079088
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
NCT01864148
Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis
NCT00390221
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis
NCT01051349
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BIIB033 (opicinumab) 750 mg
Participants with relapsing multiple sclerosis (RMS) will receive BIIB033 750 milligram (mg) intravenously (IV) as an add-on therapy to a background disease-modifying therapy (DMT) once every 4 weeks over 72 weeks in Part 1 and once every 4 weeks over 96 weeks in Part 2.
BIIB033 (opicinumab)
Administered as specified in the treatment arm
Placebo
Participants with RMS will receive placebo IV as an add-on therapy to a background DMT once every 4 weeks over 72 weeks in Part 1 and BIIB033 once every 4 weeks over 96 weeks in Part 2. The placebo looks like BIIB033 but does not contain the active ingredient that is thought to have an effect on MS disease. The placebo used in this study is sterile normal saline (water with a small amount of sodium chloride \[salt\]).
Placebo
Administered as specified in the treatment arm
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BIIB033 (opicinumab)
Administered as specified in the treatment arm
Placebo
Administered as specified in the treatment arm
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects must have experienced at least 1 of the following within 24 months prior to Day 1/Baseline: a clinical relapse (but not within 24 weeks prior to Day 1/Baseline), gadolinium-enhancing lesions on brain or spinal cord magnetic resonance imaging (MRI), or new T2 lesion(s) on brain or spinal cord MRI.
* Subjects must be on a stable dose of a protocol-specified anti-inflammatory disease-modifying therapy (DMT) (IFNβ \[Avonex, Plegridy, Betaferon/Betaseron, or Rebif\], dimethyl fumarate (DMF) \[Tecfidera\], or natalizumab \[Tysabri\]) for at least 24 weeks prior to enrollment.
* In addition, subjects must have met protocol-defined MRI characteristics using magnetization transfer ratio (MTR) and diffusion tensor imaging (DTI) sequences at Screening/Baseline.
-Subjects who complete study treatment (BIIB033 or placebo) at Part 1/Week 72 Visit.
Exclusion Criteria
* An MS relapse that has occurred within 24 weeks prior to Day 1/Baseline or the subject has not stabilized from a previous relapse at the time of Screening.
* Treatment with any chemotherapeutic agents (e.g., mitoxantrone, cyclophosphamide, cladribine), cell-depleting monoclonal antibodies (mAbs) (e.g., rituximab, ocrelizumab, alemtuzumab), total lymphoid irradiation, T-cell or T-cell receptor vaccination, or teriflunomide within 1 year prior to Day 1/Baseline.
* Treatment with other anti-inflammatory DMTs (e.g., GA, fingolimod, daclizumab) or plasmapheresis within 24 weeks prior to Day1/Baseline.
* Treatment with Botox for limb spasticity within 24 weeks before Day 1/Baseline.
* Contraindications to MRI, for example, presence of pacemakers or other implanted metal devices (excluding dental braces), an allergy to gadolinium renal impairment, or claustrophobia that cannot be medically managed.
* History of human immunodeficiency virus or other immunodeficient conditions.
* History of malignancy; however, subjects with a history of excised or treated basal cell carcinoma or fewer than 3 squamous cell carcinomas are eligible to participate in this study.
* Subjects who did not complete study treatment in Part 1/Week 72 Visit
* Subjects who have a duration \>12 weeks between their Part 1/Week 72 Visit and Part 2/Day 1.
* Contraindications to MRI, for example, presence of pacemakers or other implanted metal devices (excluding dental braces), an allergy to Gd, renal impairment, or claustrophobia that cannot be medically managed.
* History of human immunodeficiency virus or other immunodeficient conditions not related to DMT treatment.
* History of malignancy unless enrollment is approved by the Sponsor; subjects with a history of excised or treated basal cell carcinoma or fewer than 3 squamous cell carcinomas are eligible to participate in this study.
18 Years
58 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biogen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Biogen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Cullman, Alabama, United States
Research Site
Gilbert, Arizona, United States
Research Site
Berkeley, California, United States
Research Site
Long Beach, California, United States
Research Site
Newport Beach, California, United States
Research Site
Orange, California, United States
Research Site
Centennial, Colorado, United States
Research Site
Fort Collins, Colorado, United States
Research Site
Stamford, Connecticut, United States
Research Site
Washington D.C., District of Columbia, United States
Research Site
Sunrise, Florida, United States
Research Site
Tampa, Florida, United States
Research Site
Atlanta, Georgia, United States
Research Site
Chicago, Illinois, United States
Research Site
Chicago, Illinois, United States
Research Site
Overland Park, Kansas, United States
Research Site
Lexington, Kentucky, United States
Research Site
Baltimore, Maryland, United States
Research Site
Boston, Massachusetts, United States
Research Site
Boston, Massachusetts, United States
Research Site
Lexington, Massachusetts, United States
Research Site
Wellesley, Massachusetts, United States
Research Site
Farmington Hills, Michigan, United States
Research Site
Minneapolis, Minnesota, United States
Research Site
St Louis, Missouri, United States
Research Site
St Louis, Missouri, United States
Research Site
Las Vegas, Nevada, United States
Research Site
Freehold, New Jersey, United States
Research Site
Teaneck, New Jersey, United States
Research Site
Latham, New York, United States
Research Site
New York, New York, United States
Research Site
Patchogue, New York, United States
Research Site
Rochester, New York, United States
Research Site
Stony Brook, New York, United States
Research Site
Durham, North Carolina, United States
Research Site
Raleigh, North Carolina, United States
Research Site
Columbus, Ohio, United States
Research Site
Dayton, Ohio, United States
Research Site
Oklahoma City, Oklahoma, United States
Research Site
Portland, Oregon, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
Willow Grove, Pennsylvania, United States
Research Site
Knoxville, Tennessee, United States
Research Site
Memphis, Tennessee, United States
Research Site
Dallas, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Round Rock, Texas, United States
Research Site
Orem, Utah, United States
Research Site
Salt Lake City, Utah, United States
Research Site
Seattle, Washington, United States
Research Site
Seattle, Washington, United States
Research Site
Box Hill, Victoria, Australia
Research Site
Clayton, Victoria, Australia
Research Site
Heidelberg, Victoria, Australia
Research Site
Melbourne, Victoria, Australia
Research Site
Parkville, Victoria, Australia
Research Site
New Lambton Heights, , Australia
Research Site
Westmead, , Australia
Research Site
Bruges, , Belgium
Research Site
Brussels, , Belgium
Research Site
Brussels, , Belgium
Research Site
Ghent, , Belgium
Research Site
La Louvière, , Belgium
Research Site
Leuven, , Belgium
Research Site
Roeselare, , Belgium
Research Site
Edmonton, Alberta, Canada
Research Site
Vancouver, British Columbia, Canada
Research Site
Victoria, British Columbia, Canada
Research Site
Ottawa, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Gatineau, Quebec, Canada
Research Site
Longueuil, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Brno, , Czechia
Research Site
Brno, , Czechia
Research Site
Hradec Králové, , Czechia
Research Site
Jihlava, , Czechia
Research Site
Pardubice, , Czechia
Research Site
Prague, , Czechia
Research Site
Strasbourg, Bas Rhin, France
Research Site
Nîmes, Gard, France
Research Site
Bordeaux, Gironde, France
Research Site
Toulouse, Haute Garonne, France
Research Site
Montpellier, Herault, France
Research Site
Nantes, Loire Atlantique, France
Research Site
Lille, Nord, France
Research Site
Clermont-Ferrand, Puy De Dome, France
Research Site
Bron, Rhone, France
Research Site
Amiens, Somme, France
Research Site
Paris, , France
Research Site
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Research Site
Tübingen, Baden-Wurttemberg, Germany
Research Site
Ulm, Baden-Wurttemberg, Germany
Research Site
Munich, Bavaria, Germany
Research Site
Bochum, North Rhine-Westphalia, Germany
Research Site
Düsseldorf, North Rhine-Westphalia, Germany
Research Site
Trier, Rhineland-Palatinate, Germany
Research Site
Dresden, Saxony, Germany
Research Site
Berlin, , Germany
Research Site
Münster, , Germany
Research Site
Budapest, , Hungary
Research Site
Budapest, , Hungary
Research Site
Budapest, , Hungary
Research Site
Esztergom, , Hungary
Research Site
Kistarcsa, , Hungary
Research Site
Pécs, , Hungary
Research Site
Ramat Gan, , Israel
Research Site
Montichiari, Brescia, Italy
Research Site
Pozzilli, Isernia, Italy
Research Site
Cefalù, Palermo, Italy
Research Site
Genova, , Italy
Research Site
Messina, , Italy
Research Site
Milan, , Italy
Research Site
Milan, , Italy
Research Site
Napoli, , Italy
Research Site
Napoli, , Italy
Research Site
Napoli, , Italy
Research Site
Pisa, , Italy
Research Site
Roma, , Italy
Research Site
Verona, , Italy
Research Site
Geleen, , Netherlands
Research Site
Bydgoszcz, , Poland
Research Site
Gdansk, , Poland
Research Site
Katowice, , Poland
Research Site
Katowice, , Poland
Research Site
Krakow, , Poland
Research Site
Lodz, , Poland
Research Site
Lublin, , Poland
Research Site
Szczecin, , Poland
Research Site
Warsaw, , Poland
Research Site
Zabrze, , Poland
Research Site
Salt, Girona, Spain
Research Site
Majadahonda, Madrid, Spain
Research Site
Barakaldo, Vizcaya, Spain
Research Site
Barcelona, , Spain
Research Site
Barcelona, , Spain
Research Site
Barcelona, , Spain
Research Site
Córdoba, , Spain
Research Site
Madrid, , Spain
Research Site
Seville, , Spain
Research Site
Aarau, , Switzerland
Research Site
Basel, , Switzerland
Research Site
Bern, , Switzerland
Research Site
Lugano, , Switzerland
Research Site
Zurich, , Switzerland
Research Site
Exeter, Devon, United Kingdom
Research Site
Plymouth, Devon, United Kingdom
Research Site
London, Greater London, United Kingdom
Research Site
London, Greater London, United Kingdom
Research Site
Salford, Greater Manchester, United Kingdom
Research Site
Liverpool, Merseyside, United Kingdom
Research Site
Nottingham, Nottinghamshire, United Kingdom
Research Site
Oxford, Oxfordshire, United Kingdom
Research Site
Glasgow, Strathclyde, United Kingdom
Research Site
Newcastle upon Tyne, Tyne & Wear, United Kingdom
Research Site
Leeds, West Yorkshire, United Kingdom
Research Site
Brighton, , United Kingdom
Research Site
Sheffield, , United Kingdom
Research Site
Swansea, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Elliott C, Rudko DA, Arnold DL, Fetco D, Elkady AM, Araujo D, Zhu B, Gafson A, Tian Z, Belachew S, Bradley DP, Fisher E. Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis. Mult Scler. 2023 May;29(6):680-690. doi: 10.1177/13524585231162262. Epub 2023 Apr 10.
Hanf KJM, Arndt JW, Liu Y, Gong BJ, Rushe M, Sopko R, Massol R, Smith B, Gao Y, Dalkilic-Liddle I, Lee X, Mojta S, Shao Z, Mi S, Pepinsky RB. Functional activity of anti-LINGO-1 antibody opicinumab requires target engagement at a secondary binding site. MAbs. 2020 Jan-Dec;12(1):1713648. doi: 10.1080/19420862.2020.1713648.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-001224-22
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
215MS202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.